| Machine learning in drug discovery and development part 1: a primer A Talevi, JF Morales, G Hather, JT Podichetty, S Kim, PC Bloomingdale, ... CPT: pharmacometrics & systems pharmacology 9 (3), 129-142, 2020 | 51 | 2020 |
| Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs GA Islan, ME Ruiz, JF Morales, ML Sbaraglini, AV Enrique, G Burton, ... Journal of Materials Chemistry B 5 (17), 3132-3144, 2017 | 29 | 2017 |
| Cascade ligand-and structure-based virtual screening to identify new trypanocidal compounds inhibiting putrescine uptake LN Alberca, ML Sbaraglini, JF Morales, R Dietrich, MD Ruiz, ... Frontiers in Cellular and Infection Microbiology 8, 173, 2018 | 22 | 2018 |
| Current state and future perspectives in QSAR models to predict blood-brain barrier penetration in central nervous system drug R&D J F Morales, S Scioli Montoto, P Fagiolino, M E Ruiz Mini reviews in medicinal chemistry 17 (3), 247-257, 2017 | 21 | 2017 |
| Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy K Lingineni, V Aggarwal, JF Morales, DJ Conrado, D Corey, C Vong, ... CPT: Pharmacometrics & Systems Pharmacology 11 (3), 318-332, 2022 | 17 | 2022 |
| Development and validation of a computational model ensemble for the early detection of BCRP/ABCG2 substrates during the drug design stage ME Gantner, RN Peroni, JF Morales, ML Villalba, ME Ruiz, A Talevi Journal of Chemical Information and Modeling 57 (8), 1868-1880, 2017 | 17 | 2017 |
| Challenges in Alzheimer's Disease Drug Discovery and Development: the role of modeling, simulation, and open data DJ Conrado, S Duvvuri, H Geerts, J Burton, C Biesdorf, M Ahamadi, ... Clinical Pharmacology & Therapeutics 107 (4), 796-805, 2020 | 12 | 2020 |
| Drug development tools in the alzheimer disease continuum (ddt-ad) working group. challenges in Alzheimer's Disease drug discovery and development: the role of modeling … DJ Conrado, S Duvvuri, H Geerts, J Burton, C Biesdorf, M Ahamadi, ... Clin Pharmacol Ther 107 (4), 796-805, 2020 | 6 | 2020 |
| Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies JF Morales, R Muse, JT Podichetty, J Burton, S David, P Lang, S Schmidt, ... CPT: Pharmacometrics & Systems Pharmacology 12 (7), 1016-1028, 2023 | 3 | 2023 |
| Positive predictive value surfaces as a complementary tool to assess the performance of virtual screening methods JF Morales, S Chuguransky, LN Alberca, JI Alice, S Goicoechea, ME Ruiz, ... Mini Reviews in Medicinal Chemistry 20 (14), 1447-1460, 2020 | 3 | 2020 |
| Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials S Kim, RJ Willcocks, MJ Daniels, JF Morales, DY Yoon, WT Triplett, ... CPT: Pharmacometrics & Systems Pharmacology 12 (10), 1437-1449, 2023 | 2 | 2023 |
| Molecular Topology and Other Promiscuity Determinants as Predictors of Therapeutic Class-A Theoretical Framework to Guide Drug Repositioning? JF Morales, LN Alberca, S Chuguransky, ME Di Ianni, A Talevi, ME Ruiz Current Topics in Medicinal Chemistry 18 (13), 1110-1122, 2018 | 2 | 2018 |
| Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles DY Yoon, MJ Daniels, RJ Willcocks, WT Triplett, JF Morales, GA Walter, ... Journal of Pharmacokinetics and Pharmacodynamics, 1-13, 2024 | | 2024 |
| Application of machine learning to predict unbound drug bioavailability in the brain JF Morales, ME Ruiz, RE Stratford, A Talevi Frontiers in Drug Discovery 4, 1360732, 2024 | | 2024 |
| P146 A clinical trial simulation tool to accelerate trial design in DMD: description of the traphical user interface features and applications R Belfiore-Oshan, V Aggarwal, J Wilk, M Pauley, D Corey, K Romero, ... Neuromuscular Disorders 33, S84, 2023 | | 2023 |
| VP. 85 C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy R Belfiore-Oshan, V Aggarwal, S Sivakumaran, D Corey, C Ollivier, ... Neuromuscular Disorders 32, S128, 2022 | | 2022 |
| 63-OR: A Model-Based Clinical Trial Simulation Tool to Optimize Clinical Trial Designs for Type 1 Diabetes Prevention Studies JF Morales, R Muse, J Podichetty, J Burton, S David, F Martin, ... Diabetes 71 (Supplement_1), 2022 | | 2022 |
| DMD–BIOMARKERS & OUTCOME MEASURES: P. 126 Development of a regulatory-ready clinical trial simulation tool for Duchenne muscular dystrophy J Larkindale, S Kim, K LIngineni, J Morales, S Schmidt, D Corey, ... Neuromuscular Disorders 30, S83, 2020 | | 2020 |
| MUSCLE IMAGING–MRI: P. 161 Development of clinical trial simulation tools for Duchenne muscular dystrophy using magnetic resonance biomarkers K Vandenborne, S Kim, R Willcocks, J Morales, K Lingineni, A Barnard, ... Neuromuscular Disorders 30, S93-S94, 2020 | | 2020 |
| Application of Machine Learning Approaches to Identify New Anticonvulsant Compounds Active in the 6 Hz Seizure Model S Goicoechea, ML Sbaraglini, SR Chuguransky, JF Morales, ME Ruiz, ... Computational Neuroscience: Second Latin American Workshop, LAWCN 2019, São …, 2019 | | 2019 |
